Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
| ▸ | TERT | O14746 | 5/20 | 0.67 |
| ▸ | TOP1 | P11387 | 4/20 | 0.56 |
| ▸ | CYCS | P99999 | 3/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinc Ion SCHEMBL31042928 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| Zinc Ion SCHEMBL11569891 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL9267975 | 0.97 | TERT (0.71) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL2334489 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL2334465 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL23706379 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL5051415 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL6139711 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL8994427 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL30205815 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-20160205925-A1 | ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2016-07-21 | — | — | US | disclosed |
| US-9226917-B2 | Photodynamic therapy for conditions of the eye | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-8968715-B2 | Drug delivery systems for photodynamic therapy | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8852629-B2 | Drug delivery system for hydrophobic drugs | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2014-10-07 | — | — | US | disclosed |
| US-8211656-B2 | Biological targeting compositions and methods of using the same | THE INVENTION SCIENCE FUND I, LLC (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| US-20120134975-A1 | Biological targeting compositions and methods of using the same | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2012-05-31 | — | — | US | disclosed |
| EP-1357912-B1 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-04-25 | — | — | EP | disclosed |
| US-20120041356-A1 | PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE | QLT INC. (CA) | 2012-02-16 | — | — | US | disclosed |
| US-20030099596-A1 | Treatment of macular edema | BAUSCH HEALTH IRELAND LIMITED (IE) | 2003-05-29 | — | — | US | disclosed |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-05-08 | — | — | US | disclosed |
| US-20030083649-A1 | Method for reducing or preventing PDT related inflammation | VALEANT SP. Z.O.O. (PL) | 2003-05-01 | — | — | US | disclosed |
| WO-2003028628-A2 | PHOTOSENSITIZING CARBAMATE DERIVATIVES | MIRAVANT PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20020183302-A1 | Method to prevent vision loss | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020173832-A1 | Reduced fluence rate PDT | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-11-21 | — | — | US | disclosed |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | BAUSCH HEALTH COMPANIES INC. (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030099596-A1 | Treatment of macular edema | VEGFA, PPOX, FLT4 | ENPP2 2107/4885TERT 2574/4885TOP1 4413/4885 |
| US-20020183302-A1 | Method to prevent vision loss | VEGFA, ALDH1A2, PDE6C | ENPP2 961/4885TERT 2302/4885TOP1 3120/4885 |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | LIPA, MLEC, ABCG2 | ENPP2 3780/4885TERT 4251/4885TOP1 3220/4885 |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | PIN1, PPOX, DHFR | ENPP2 1120/4885TERT 3224/4885TOP1 1303/4885 |
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | ENPP2 889/4885TERT 2853/4885TOP1 1254/4885 |
| US-20160205925-A1 | ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER | CUTA, POLR1C, PUF60 | ENPP2 3665/4885TERT 563/4885TOP1 738/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | ENPP2 100/4885TERT 2006/4885TOP1 1012/4885 |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | ALDH1A2, AGER, CRY2 | ENPP2 442/4885TERT 559/4885TOP1 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.